Gladstone NOW: The Campaign Join Us on the Journey ✕
16 - 30 of 430 Results Clear All
The New York Times—Katie Pollard, director of the Gladstone Institute of Data Science and Biotechnology, comments on how the 4D Nucleome Project is revealing the way DNA misfolding inside the nucleus can contribute to disease. (Subscription required.)
Gladstone Experts Pollard Lab
The Daily Northwestern—Katie Pollard, director of the Gladstone Institute of Data Science and Biotechnology, explains how the 4D Nucleome Project mapped the genome in 3D to understand how the folding of chromosomes relates to DNA function.
Gladstone Experts Pollard Lab
The Stem Cell Podcast—Gladstone President and Investigator Deepak Srivastava discusses groundbreaking research on heart defects in Down syndrome and ways to encourage the growth of cell and gene therapies.
Gladstone Experts Cardiovascular Disease Srivastava Lab
Development—Gladstone scientists Irfan Kathiriya and Benoit Bruneau comment on their study, which identified the gene TBX5 as a key regulator of the gene regulatory networks governing atrial cell type specification and a potential therapeutic target for genetic atrial diseases.
Gladstone Experts Congenital Heart Disease Cardiovascular Disease Bruneau Lab
The Washington Post—As the National Institutes of Health announced it would no longer support research that utilizes fetal tissue, Gladstone Investigator Steve Finkbeiner explains the importance of using this model to better understand Alzheimer’s disease. (Subscription required.)
Gladstone Experts Finkbeiner Lab
Nature—Gladstone Investigator Steve Finkbeiner comments on new restrictions that many scientists believe will slow research on fetal development and stem-cell biology.
Gladstone Experts Finkbeiner Lab
The AI Journal—A collaboration between Topos Bio and the team led by Steve Finkbeiner, director of the Center for Systems and Therapeutics at Gladstone, aims to apply a new approach to neurodegenerative disease.
Gladstone Experts Alzheimer’s Disease Neurological Disease Finkbeiner Lab
From fundamental insights to translational advances, here’s how Gladstone researchers moved science forward in 2025.
Gladstone Experts Alzheimer’s Disease Autoimmune Diseases COVID-19 Neurological Disease Genomic Immunology Cardiovascular Disease Data Science and Biotechnology Infectious Disease Conklin Lab
Global Wellness Summit—Gladstone President Deepak Srivastava was honored with the Bennett Family Award for Collaboration in the Science of Wellness, recognizing his leadership in bringing together experts across disciplines to accelerate discoveries that will define the next era of human health.
Gladstone Experts Srivastava Lab
Innovative Genomics Institute—A team of researchers, including Gladstone Investigator Jennifer Doudna, reveal that viruses have evolved a surprisingly large and diverse set of enzymes specifically designed to destroy immune alarm signals from cells, helping them disable the host’s antiviral defenses.
Gladstone Experts Infectious Disease Doudna Lab
Earth.com—A study by Gladstone Investigator Ken Nakamura helps answer a long-standing debate about Parkinson’s disease: do the cell’s tiny energy factories fail first and spark the disorder, or do they crumble only after brain cells have already begun to die?
Gladstone Experts Parkinson’s Disease Neurological Disease Nakamura Lab
Inside Precision Medicine—A new study by Gladstone Investigator Ken Nakamura has found that a mitochondrial protein, CHCHD2, can drive a sequence of cellular events that lead to the development Parkinson’s disease.
Gladstone Experts Parkinson’s Disease Neurological Disease Nakamura Lab
CRISPR Medicine News—Gladstone Investigator Bruce Conklin showed how manipulating DNA repair responses in neurons after CRISPR editing can direct outcomes and improve editing efficiency.
Gladstone Experts Neurological Disease Conklin Lab CRISPR/Gene Editing
Potrero View—This profile of Katie Pollard, director of the Gladstone Institute of Data Science and Biotechnology, describes how she became one of the world’s leading scientists in computational genomics, and how her team is using artificial intelligence to decode the fundamental language of life itself.
Gladstone Experts Pollard Lab
Azalea Therapeutics—Gladstone Investigators Jennifer Doudna and Justin Eyquem founded a new company to advance next-generation genomic medicines.
Business Development Gladstone Experts Doudna Lab Eyquem Lab
